



## **ACADIA Pharmaceuticals to Announce First Quarter 2009 Financial Results on May 11, 2009**

May 5, 2009

### **ACADIA to Host Conference Call and Webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time**

SAN DIEGO--(BUSINESS WIRE)--May. 5, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2009 on Monday, May 11, 2009, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.

The conference call may be accessed by dialing 866-825-3209 for participants in the U.S. or Canada and 617-213-8061 for international callers (reference passcode 62919191). A telephone replay of the conference call may be accessed through May 25, 2009 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 93775458). The conference call also will be webcast live on ACADIA's website, [www.acadia-pharm.com](http://www.acadia-pharm.com), under the investors section and will be archived there until May 25, 2009.

#### *About ACADIA Pharmaceuticals*

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA's most advanced product candidates include pimavanserin in Phase III for Parkinson's disease psychosis in collaboration with Biovail Laboratories International SRL, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as additional compounds in IND-track development. All of the product candidates in ACADIA's pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at [www.acadia-pharm.com](http://www.acadia-pharm.com) to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

Source: ACADIA Pharmaceuticals Inc.

*ACADIA Pharmaceuticals Inc.*

*Lisa Barthelemy, Director, Investor Relations*

*Thomas H. Aasen, Vice President and Chief Financial Officer*  
*(858) 558-2871*